{"id":10641,"date":"2021-07-20T13:34:26","date_gmt":"2021-07-20T10:34:26","guid":{"rendered":"http:\/\/blog.ulubat.org\/?p=10641"},"modified":"2021-07-20T13:55:08","modified_gmt":"2021-07-20T10:55:08","slug":"alzheimera-ilk-onayli-tedaviaduhelm-peki-ya-tartismalar","status":"publish","type":"post","link":"https:\/\/blog.ulubat.org\/index.php\/haberler\/alzheimera-ilk-onayli-tedaviaduhelm-peki-ya-tartismalar\/","title":{"rendered":"ALZHE\u0130MERA \u0130LK ONAYLI TEDAV\u0130:ADUHELM. PEK\u0130 YA TARTI\u015eMALAR?"},"content":{"rendered":"\n<figure class=\"wp-container-2 wp-block-gallery-1 wp-block-gallery columns-1 is-cropped\"><ul class=\"blocks-gallery-grid\"><li class=\"blocks-gallery-item\"><figure><img loading=\"lazy\" width=\"1024\" height=\"768\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-1024x768.jpg\" alt=\"\" data-id=\"10645\" class=\"wp-image-10645\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-1024x768.jpg 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-400x300.jpg 400w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-768x576.jpg 768w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-110x83.jpg 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-420x315.jpg 420w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920-573x430.jpg 573w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dependent-107079_1920.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"blocks-gallery-item__caption\"><br><br><br>https:\/\/pixabay.com\/tr\/photos\/ba%c4%9f%c4%b1ml%c4%b1-demans-kad%c4%b1n-eski-ya%c5%9f-107079\/<\/figcaption><\/figure><\/li><\/ul><\/figure>\n\n\n\n<p>Alzheimer hastal\u0131\u011f\u0131, ya\u015fl\u0131 eri\u015fkinlerde demans\u0131n en \u00f6nemli nedenidir ve ya\u015fla insidans\u0131 artar. Hastal\u0131k, genelde y\u00fcksek kognitif fonksiyonlarda sinsi ba\u015flang\u0131\u00e7l\u0131 bozulma, haf\u0131za kayb\u0131 ile de\u011fi\u015fen duygudurum ve davran\u0131\u015flarla kendini g\u00f6sterir. Alzheimer hastal\u0131\u011f\u0131ndaki temel anormallik amiloid beta ve tau proteinin beynin belli b\u00f6lgelerinde s\u0131ras\u0131yla plaklar ve yumaklar \u015feklinde birikmesidir. Bu de\u011fi\u015fiklikler n\u00f6ronal disfonksiyon, n\u00f6ron \u00f6l\u00fcm\u00fc ve inflamatuar reaksiyonlar gibi ikincil etkiler do\u011furur.<\/p>\n\n\n\n<p>FDA taraf\u0131ndan marka ad\u0131 <em>Aduhelm<\/em> olarak ge\u00e7en monoklonal antikor &#8220;aducanumab&#8221;<em> <\/em>i\u00e7in Alzheimer hastal\u0131\u011f\u0131n\u0131n erken evrelerinin tedavisinde kullan\u0131m\u0131na onay verildi. 7 Haziran 2021&#8217;de yap\u0131lan bu duyuru ile FDA, bu n\u00f6rodejeneratif hastal\u0131\u011f\u0131n tedavisi i\u00e7in son 17 y\u0131lda ilk kez bir ilaca onay vermi\u015f oldu. Bilim insanlar\u0131n\u0131n bir\u00e7o\u011funa g\u00f6re bu ila\u00e7 Alzheimer tedavisinde yeni bir umut olarak \u00e7\u0131\u011f\u0131r a\u00e7acak. Bu olumlu tutumun aksine ilaca olumsuz bakanlar\u0131n say\u0131s\u0131 ise az\u0131msanamayacak kadar \u00e7ok.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-1024x1024.jpg\" alt=\"\" class=\"wp-image-10653\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-1024x1024.jpg 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-150x150.jpg 150w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-250x250.jpg 250w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-125x125.jpg 125w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-110x110.jpg 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-1536x1536.jpg 1536w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-2048x2048.jpg 2048w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-420x420.jpg 420w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-400x400.jpg 400w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/4419109129_35fdd2e0a0_o-2-768x768.jpg 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3>3 FDA dan\u0131\u015fman\u0131 ilac\u0131n onaylanmas\u0131yla istifa etti.<\/h3>\n\n\n\n<p>&nbsp;Ge\u00e7ti\u011fimiz g\u00fcnlerde yap\u0131lan bir panelde FDA&#8217;ya dan\u0131\u015fmanl\u0131k yapan \u00fc\u00e7 bilim insan\u0131, bahsi ge\u00e7en ilac\u0131n onaylanmas\u0131n\u0131n ard\u0131ndan istifalar\u0131n\u0131 verdi.&nbsp;Dr. Aaron Kesselheim,&nbsp;New York Times&#8217;a konu\u015furken bu karar\u0131<em>&nbsp;&#8220;hat\u0131rlayabildi\u011fi kadar\u0131yla FDA&#8217;n\u0131n en k\u00f6t\u00fc karar\u0131<\/em>&#8221; olarak nitelendirdi.<\/p>\n\n\n\n<h2><strong>Bu yeni tedavi nedir? Nas\u0131l i\u015fler?<\/strong><\/h2>\n\n\n\n<p>Aduhelm,&nbsp;amiloid betay\u0131 hedefleyen&nbsp;bir&nbsp;antikordur.&nbsp;Antikor&nbsp;tercihen k\u00fcmelenmi\u015f amiloid betaya ba\u011flan\u0131r. Bunun nedeni, amiloid beta monomerinde normalde eri\u015filemeyen&nbsp;bir&nbsp;epitopu&nbsp;hedeflemesidir.&nbsp;Bu etkile\u015fim sayesinde, Aduhelm beyinde bulunan amiloid plaklar\u0131n\u0131n say\u0131s\u0131n\u0131 azaltarak potansiyel olarak n\u00f6rodejenerasyonu ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatabilir. Ancak baz\u0131 doktorlar, amiloidin \u00e7\u0131kar\u0131lmas\u0131n\u0131n hastal\u0131\u011f\u0131n ilerlemesini yava\u015flat\u0131p yava\u015flatmayaca\u011f\u0131n\u0131n belirsiz oldu\u011funu s\u00f6yl\u00fcyor. Ba\u015flang\u0131\u00e7ta t\u00fcm Alzheimer hastalar\u0131 i\u00e7in tedaviyi onaylayan FDA, al\u0131nan tepkilerden sonra re\u00e7eteleme talimatlar\u0131n\u0131 daraltt\u0131. Tedavinin sadece hastal\u0131\u011f\u0131n erken evre semptomlar\u0131 olan ki\u015filere verilmesini \u00f6nerdi. Tedavi g\u00f6ren hastalar, tedavinin en yayg\u0131n yan etkileri olan k\u00fc\u00e7\u00fck beyin kanamalar\u0131 veya beyin \u015fi\u015fmesi&nbsp; geli\u015ftirip geli\u015ftirmediklerini g\u00f6rmek i\u00e7in periyodik MRI taramalar\u0131 da almal\u0131d\u0131r.<\/p>\n\n\n\n<h2><strong>\u0130la\u00e7 neden tart\u0131\u015fmal\u0131d\u0131r?<\/strong><\/h2>\n\n\n\n<p>Ara\u015ft\u0131rma komitesi, Aduhelm&#8217;in hastal\u0131\u011f\u0131n erken evrelerinde insanlarda bili\u015fsel gerilemeyi yava\u015flatabilece\u011fine dair ikna edici bir kan\u0131t g\u00f6stermedi\u011fini ve ilac\u0131n beyin \u015fi\u015fmesi ve beyin kanamas\u0131 gibi potansiyel olarak ciddi yan etkilere neden olabilece\u011fini belirtti.&nbsp;Komitenin 11 \u00fcyesinden 10\u2019u aleyhte oy kullan\u0131rken bir \u00fcye ise \u00e7ekimser oy kulland\u0131.<\/p>\n\n\n\n<p>Ara\u015ft\u0131rma komitesinden ilk istifa eden doktor olan Joel Perlmutter, etkili olmayan bir ilac\u0131n onaylanmas\u0131n\u0131n, etkili olabilecek yeni tedavilere y\u00f6nelik gelecekteki ara\u015ft\u0131rmalar\u0131 bozma konusunda ciddi bir potansiyele sahip oldu\u011funu ifade etti. Ayr\u0131ca milyarlarca dolara mal olan bu tedaviyi uygulamak yerine bu dolarlarla daha kesin kan\u0131tlar geli\u015ftirilerek tedavi daha g\u00fcvenilir bir hale getirilebilir.<\/p>\n\n\n\n<p>Aducanumab klinik deneylerinde \u00e7al\u0131\u015fan baz\u0131 doktorlar da&nbsp;dahil olmak \u00fczere bir\u00e7ok sayg\u0131n uzman,&nbsp;mevcut&nbsp;kan\u0131tlar\u0131n&nbsp;ilac\u0131n etkili olup olmad\u0131\u011f\u0131&nbsp;konusunda \u00f6nemli \u015f\u00fcpheler uyand\u0131rd\u0131\u011f\u0131n\u0131&nbsp;s\u00f6yledi.&nbsp;Ayr\u0131ca, baz\u0131 hastalarda bili\u015fsel gerilemeyi yava\u015flatabilse bile, beklenen yarar\u0131n &#8211; 18 ay boyunca yakla\u015f\u0131k d\u00f6rt ay boyunca semptomlar\u0131n yava\u015flamas\u0131 &#8211; hastalar taraf\u0131ndan zar zor fark edilebilece\u011fini ve beyne olan yan etki risklerinden daha a\u011f\u0131r basamayaca\u011f\u0131n\u0131 ifade ettiler.<\/p>\n\n\n\n<p>\u0130lac\u0131n y\u00fcksek fiyat etiketinin (56 milyar dolar) \u00f6tesinde, hastalar\u0131 tedaviden \u00f6nce taramak ve beyinlerini sorunlara kar\u015f\u0131 izlemek i\u00e7in gereken d\u00fczenli MRI&#8217;lar i\u00e7in ek maliyetler, sekmeye on binlerce dolar ekleyebilir.&nbsp;<\/p>\n\n\n\n<h2><strong>Aduhelm kimler i\u00e7in uygundur?<\/strong><\/h2>\n\n\n\n<div class=\"wp-container-5 wp-block-group\"><div class=\"wp-block-group__inner-container\">\n<figure class=\"wp-container-4 wp-block-gallery-3 wp-block-gallery columns-1 is-cropped\"><ul class=\"blocks-gallery-grid\"><li class=\"blocks-gallery-item\"><figure><img loading=\"lazy\" width=\"1024\" height=\"534\" src=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-1024x534.jpg\" alt=\"\" data-id=\"10648\" class=\"wp-image-10648\" srcset=\"https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-1024x534.jpg 1024w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-400x209.jpg 400w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-768x401.jpg 768w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-110x57.jpg 110w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-420x219.jpg 420w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1-770x402.jpg 770w, https:\/\/blog.ulubat.org\/wp-content\/uploads\/2021\/07\/dementia-3051832_1920-1.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"blocks-gallery-item__caption\">https:\/\/pixabay.com\/tr\/photos\/demans-alzheimer-ba%c4%9f%c4%b1ml%c4%b1-unutmak-3051832\/<\/figcaption><\/figure><\/li><\/ul><\/figure>\n<\/div><\/div>\n\n\n\n<p>Aduhelm, FDA\u2019in son karar\u0131yla sadece hastal\u0131\u011f\u0131n erken evrelerindeki hastalar i\u00e7in \u00f6nerilmektedir. Doktorlar tedaviyi almas\u0131 gereken hastalar\u0131n daha hafif haf\u0131za semptomlar\u0131 olan veya hastal\u0131\u011f\u0131n erken evrelerinde olan hastalar oldu\u011fu konusunda hemfikirdir. \u00c7\u00fcnk\u00fc \u00e7al\u0131\u015fmalar bu hastalar \u00fczerinde test edilmi\u015ftir.<\/p>\n\n\n\n<h2><strong>KAYNAK\u00c7A:<\/strong><\/h2>\n\n\n\n<ol type=\"1\"><li><em><strong><a href=\"https:\/\/alzheimersnewstoday.com\/aducanumab\/\">https:\/\/alzheimersnewstoday.com\/aducanumab\/<\/a><\/strong><\/em><\/li><li><em><strong><a href=\"https:\/\/www.nytimes.com\/2021\/06\/10\/health\/aduhelm-fda-resign-alzheimers.html\">https:\/\/www.nytimes.com\/2021\/06\/10\/health\/aduhelm-fda-resign-alzheimers.html<\/a><\/strong><\/em><\/li><li><em><strong><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug<\/a><\/strong><\/em><\/li><li><em><strong><a href=\"https:\/\/www.wsj.com\/articles\/new-alzheimers-drug-what-doctors-want-you-to-know-about-aduhelm-11624902330\">https:\/\/www.wsj.com\/articles\/new-alzheimers-drug-what-doctors-want-you-to-know-about-aduhelm-11624902330<\/a><\/strong><\/em><\/li><li><em>Kumar,V. ve di\u011f.(2013)Robin\u2019s Temel Patoloji.10.Bask\u0131.Nobel T\u0131p Kitabevleri,Fatih-\u0130stanbul,874-875.<\/em><\/li><\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer hastal\u0131\u011f\u0131, ya\u015fl\u0131 eri\u015fkinlerde demans\u0131n en \u00f6nemli nedenidir ve ya\u015fla insidans\u0131 artar. Hastal\u0131k, genelde y\u00fcksek kognitif fonksiyonlarda sinsi ba\u015flang\u0131\u00e7l\u0131 bozulma,<\/p>\n","protected":false},"author":387,"featured_media":10646,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[5,19,165],"tags":[2108,2103,2106,2107,2105,2104],"acf":[],"views":1101,"_links":{"self":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts\/10641"}],"collection":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/users\/387"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/comments?post=10641"}],"version-history":[{"count":3,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts\/10641\/revisions"}],"predecessor-version":[{"id":10654,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/posts\/10641\/revisions\/10654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/media\/10646"}],"wp:attachment":[{"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/media?parent=10641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/categories?post=10641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.ulubat.org\/index.php\/wp-json\/wp\/v2\/tags?post=10641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}